Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 4/2012

01-12-2012 | Original Article

Screening for Cushing’s syndrome in obese type 2 diabetic patients and the predictive factors on the degree of serum cortisol suppression

Authors: Meral Mert, Mustafa Temizel, Selahattin Erol, Yucel Arman, Kadem Arslan, Feride Alakus, Ebru Ayozturk Velioglu

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2012

Login to get access

Abstract

The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese type 2 diabetic patients devoid of specific clinical symptoms of Cushing’s syndrome. A total of 148 obese (BMI ≥30 kg/m2 ) type 2 diabetic patients (113 female, 35 male) were included in the study. An overnight 1-mg dexamethasone suppression test (DST) was performed on all patients. Suppression of serum cortisol to <1.8 μg/dL after administration of 1 mg dexamethasone was considered normal suppression. Low dose dexamethasone suppression test was performed on the patients who had serum cortisol level over 1.8 μg/dL after overnight 1 mg DST. Regression analysis was applied to determine the effective factors on suppression of serum cortisol. Mean age, BMI and HbA1c levels respectively were 50,82 ± 8,50 year, 31,78 ± 4,66 kg/m2, %8,96 ± 2,42 in males and 54,15 ± 10,348 year, 34,32 ± 5.71 kg/m2, % 8,18 ± 2,06 in females. Serum cortisol level was found 1.64 ± 5.62 μg/dl after overnight DST. A total of 9 (6.2 %) patients had non-suppressible overnight DST. Only four (2.6 %) of these patients were diagnosed with Cushing Syndrome after low-dose DST. Diagnosis was confirmed pathologically. Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (2 patients) and adrenocortical adenoma (2 patients). Age and duration of diabetes was found to be related to the degree of suppression. Cushing’s syndrome should be investigated in high-risk groups like uncontrolled diabetes, obesity. All the related factors on the degree of suppression must be considered for the final diagnosis.
Literature
1.
go back to reference Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslin’s Diabetes Mellitus. 14th ed. Boston: Lippincott Williams-Wilkins; 2005. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslin’s Diabetes Mellitus. 14th ed. Boston: Lippincott Williams-Wilkins; 2005.
2.
go back to reference Khan R. Weight gain and insulin therapy. Br J Diabetes Vasc Dis. 2004;4:264–7.CrossRef Khan R. Weight gain and insulin therapy. Br J Diabetes Vasc Dis. 2004;4:264–7.CrossRef
3.
go back to reference Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalance of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205–11.PubMedCrossRef Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalance of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205–11.PubMedCrossRef
4.
go back to reference De Groot LJ, editor. Endocrinology. 5th ed. Philadelphia: WB Saunders; 2001. De Groot LJ, editor. Endocrinology. 5th ed. Philadelphia: WB Saunders; 2001.
5.
go back to reference Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clin Endocrinol Metab. 2001;86:5301–6.PubMedCrossRef Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clin Endocrinol Metab. 2001;86:5301–6.PubMedCrossRef
6.
go back to reference Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.PubMedCrossRef Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.PubMedCrossRef
7.
go back to reference Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergot N, et al. Occult Cushing’s syndrome in type-2 ciabetes. J Clin Endocrinol Metab. 2003;12:5808–13.CrossRef Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergot N, et al. Occult Cushing’s syndrome in type-2 ciabetes. J Clin Endocrinol Metab. 2003;12:5808–13.CrossRef
8.
go back to reference Tabarin A, Perez P. Pros and cons of screening for occult Cushing syndrome. Nat Rev Endocrinol. 2011;7:445–55.PubMedCrossRef Tabarin A, Perez P. Pros and cons of screening for occult Cushing syndrome. Nat Rev Endocrinol. 2011;7:445–55.PubMedCrossRef
9.
go back to reference Caetano MS, Silva Rdo C, Kater CE. Increased diagnostic probability of subclinical Cushing’s syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2007;51:1118–27.PubMedCrossRef Caetano MS, Silva Rdo C, Kater CE. Increased diagnostic probability of subclinical Cushing’s syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2007;51:1118–27.PubMedCrossRef
10.
go back to reference Reimondo G, Pia A, Allasino B, Tassone F, Bovio S, Borretta G, et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol. 2007;67:225–9.CrossRef Reimondo G, Pia A, Allasino B, Tassone F, Bovio S, Borretta G, et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol. 2007;67:225–9.CrossRef
11.
go back to reference Christy NP. Harvey Cushing as clinical investigator and laboratory worker. Am J Med Sci. 1981;281:79–96.PubMedCrossRef Christy NP. Harvey Cushing as clinical investigator and laboratory worker. Am J Med Sci. 1981;281:79–96.PubMedCrossRef
12.
go back to reference Yanovski JA, Cutler Jr GB. Glucocorticoid action and the clinical features of Cushing’s syndrome. Endocrinol Metab Clin North Am. 1994;23:487–509.PubMed Yanovski JA, Cutler Jr GB. Glucocorticoid action and the clinical features of Cushing’s syndrome. Endocrinol Metab Clin North Am. 1994;23:487–509.PubMed
13.
go back to reference Leibowitz G, Tsur A, Chayen SD, et al. Preclinical Cushing’s syndrome: an unexpected frequent cause of poor glycemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44:717–22.CrossRef Leibowitz G, Tsur A, Chayen SD, et al. Preclinical Cushing’s syndrome: an unexpected frequent cause of poor glycemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44:717–22.CrossRef
14.
go back to reference Tiryakioglu O,Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO et al. Screening for Cushing's syndrome in obese patients. Clinics 2010. http://dx.doi.org/10.1590/S1807-59322010000100003. Tiryakioglu O,Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO et al. Screening for Cushing's syndrome in obese patients. Clinics 2010. http://​dx.​doi.​org/​10.​1590/​S1807-5932201000010000​3.
15.
go back to reference Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.PubMedCrossRef Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.PubMedCrossRef
16.
go back to reference Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, et al. Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res. 2002;10:1217–21.PubMedCrossRef Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, et al. Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res. 2002;10:1217–21.PubMedCrossRef
17.
go back to reference Sahin M, Kebapcilar L, Taslipinar A, Azal O, Ozgurtas T, Corakci A, et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med. 2009;48:33–9.PubMedCrossRef Sahin M, Kebapcilar L, Taslipinar A, Azal O, Ozgurtas T, Corakci A, et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med. 2009;48:33–9.PubMedCrossRef
Metadata
Title
Screening for Cushing’s syndrome in obese type 2 diabetic patients and the predictive factors on the degree of serum cortisol suppression
Authors
Meral Mert
Mustafa Temizel
Selahattin Erol
Yucel Arman
Kadem Arslan
Feride Alakus
Ebru Ayozturk Velioglu
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
International Journal of Diabetes in Developing Countries / Issue 4/2012
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-012-0091-1

Other articles of this Issue 4/2012

International Journal of Diabetes in Developing Countries 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.